Search research articles
Contact Us
Filters
Showing results (31-40 of 75) with videos related to
Page
of 8
Sort By:
Diabetes, Obesity & Metabolism
|
April 20, 2022
Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial
Wenying Yang, Xiaolin Dong, Qingju Li, et al.
Diabetes, Obesity & Metabolism
|
December 5, 2024
A biweekly DPP-4 inhibitor cofrogliptin monotherapy in Chinese patients with impaired glucose tolerance: A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial
Qinghua He, Zhifeng Cheng, Yufeng Li, et al.
American Journal of Cancer Research
|
August 8, 2024
STAC3 as a poor prognostic biomarker in renal clear cell carcinoma: relationship with immune infiltration
Yingnan Zhang, Jingtao Li, Luwen Feng, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD
|
June 12, 2024
Efficacy and safety of ongericimab given by prefilled syringe or autoinjector in primary hypercholesterolemia and mixed hyperlipidemia
Wang Zhao, Zhifeng Cheng, Xianyou Ji, et al.
Diabetes
|
February 6, 2024
Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China
Lixin Guo, Qi Pan, Zhifeng Cheng, et al.
Journal of Diabetes and Its Complications
|
December 2, 2017
Epidemiological characteristics of lower extremity arterial disease in Chinese diabetes patients at high risk: a prospective, multicenter, cross-sectional study
Xiaomei Zhang, Xingwu Ran, Zhangrong Xu, et al.
Diabetes, Obesity & Metabolism
|
May 7, 2025
Predicting 10-year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT-CN trial
Lin Zhao, Feng Tao, Zhifeng Cheng, et al.
Med (New York, N.Y.)
|
March 24, 2026
Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m<sup>2</sup> but without diabetes: A phase 2 randomized controlled trial
Linong Ji, Hongwei Jiang, Zhifeng Cheng, et al.
The Review of Scientific Instruments
|
January 29, 2025
Performance characterization of x-ray crystal spectroscopy highly oriented pyrolytic graphite reflectors based on x-ray diffractometry experiments
Dian Lu, Zhifeng Cheng, Tianlei Zhao, et al.
Communications Medicine
|
March 15, 2026
Interactions of SARS-CoV-2, influenza and respiratory syncytial virus influence epidemic timing and risk
Yonghong Liu, Xiaoli Wang, Mengyao Li, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 75) with videos related to
Sort By:
Page
of 8
Diabetes, Obesity & Metabolism
|
April 20, 2022
Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial
Wenying Yang, Xiaolin Dong, Qingju Li, et al.
Diabetes, Obesity & Metabolism
|
December 5, 2024
A biweekly DPP-4 inhibitor cofrogliptin monotherapy in Chinese patients with impaired glucose tolerance: A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial
Qinghua He, Zhifeng Cheng, Yufeng Li, et al.
American Journal of Cancer Research
|
August 8, 2024
STAC3 as a poor prognostic biomarker in renal clear cell carcinoma: relationship with immune infiltration
Yingnan Zhang, Jingtao Li, Luwen Feng, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD
|
June 12, 2024
Efficacy and safety of ongericimab given by prefilled syringe or autoinjector in primary hypercholesterolemia and mixed hyperlipidemia
Wang Zhao, Zhifeng Cheng, Xianyou Ji, et al.
Diabetes
|
February 6, 2024
Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China
Lixin Guo, Qi Pan, Zhifeng Cheng, et al.
Journal of Diabetes and Its Complications
|
December 2, 2017
Epidemiological characteristics of lower extremity arterial disease in Chinese diabetes patients at high risk: a prospective, multicenter, cross-sectional study
Xiaomei Zhang, Xingwu Ran, Zhangrong Xu, et al.
Diabetes, Obesity & Metabolism
|
May 7, 2025
Predicting 10-year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT-CN trial
Lin Zhao, Feng Tao, Zhifeng Cheng, et al.
Med (New York, N.Y.)
|
March 24, 2026
Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m<sup>2</sup> but without diabetes: A phase 2 randomized controlled trial
Linong Ji, Hongwei Jiang, Zhifeng Cheng, et al.
The Review of Scientific Instruments
|
January 29, 2025
Performance characterization of x-ray crystal spectroscopy highly oriented pyrolytic graphite reflectors based on x-ray diffractometry experiments
Dian Lu, Zhifeng Cheng, Tianlei Zhao, et al.
Communications Medicine
|
March 15, 2026
Interactions of SARS-CoV-2, influenza and respiratory syncytial virus influence epidemic timing and risk
Yonghong Liu, Xiaoli Wang, Mengyao Li, et al.
Page
of 8